ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2012 • ACR Convergence 2022

    Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis

    Yasmin Khader, Azizullah Beran, Sami Ghazaleh, Rawish Fatima, Ashu Acharya and Nezam Altorok, University of Toledo, Toledo, OH

    Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) have emerged as an effective treatment of rheumatoid arthritis (RA), improving patients’ quality of life throughout the disease course.…
  • Abstract Number: 2019 • ACR Convergence 2022

    Fine Mapping of the Sjögren’s Disease and Systemic Lupus Erythematosus DDX6-CXCR5 Risk Interval Reveals Common SNPs with Functional Significance in Immune and Salivary Gland Cells

    Mandi Wiley1, Bhuwan Khatri1, Kandice Tessneer1, Michelle Joachims1, Anna Stolarczyk1, Anna Nagel1, Astrid Rasmussen1, Professor Simon Bowman2, Lida Radfar3, Roald Omdal4, Marie Wahren-Herlenius5, Blake Warner6, Torsten Witte7, Roland Jonsson8, Maureen Rischmueller9, Patrick Gaffney1, Judith James1, Lars Ronnblom10, Hal Scofield1, Xavier Mariette11, Fai Ng12, Gunnel Nordmark10, Betty Tsao13 and Christopher Lessard1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University Hospitals Birmingham, Birmingham, United Kingdom, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Stavanger University, Stavanger, Norway, 5Karolinska Institutet, Stockholm, Sweden, 6National Institutes of Health, Bethesda, MD, 7MH-Hannover, Hannover, Germany, 8University of Bergen, Bergen, Norway, 9RheumatologySA, Adelaide, Australia, 10Uppsala University, Uppsala, Sweden, 11Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 12Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 13Medical University of South Carolina, Charleston, SC

    Background/Purpose: Sjögren's Disease (SjD) and Systemic Lupus Erythematosus (SLE) share several characteristics and have similar genome-wide significant associations in the DDX6-CXCR5 locus. Fine mapping of…
  • Abstract Number: 2022 • ACR Convergence 2022

    Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study

    Gregoire Martin de Fremont1, Nathalie Costedoat-Chalumeau2, Rakiba Belkhir3, Gaelle Guettrot-Imbert4, Nathalie Morel4, Gaetane Nocturne5, Anna Molto6, Tiphaine Goulenok7, Elisabeth Diot8, Estibaliz Lazaro9, Laurent Perard10, Nicole Ferreira11, Maelle Le Besnerais12, Nicolas Limal7, Nihal Martis13, Noémie Abisror14, Odile Debouverie15, Christophe Richez16, Vincent Sobanski17, Francois Maurier18, Gaetan Sauvetre12, Herve Levesque12, Marie Agnes Timsit19, Nathalie Tieule13, Pauline Orquevaux20, GEFA Collaborative group21, Matthieu Mahevas22, Celine Lartigau Roussin23, Elodie Chauvet24, Emilie Berthoux25, Francoise Sarrot Reynauld26, Loic Raffray27, Marion Couderc28, Nicolas Martin Silva29, Noemie Jourde Chiche30, Nicolas Belhomme31, Thierry Thomas32, Vincent Poindron33, Viviane Queyrel13, Juliette Delforge34, Camille Le Ray35, Emmanuelle Pannier35, Xavier Mariette36, Veronique Le Guern4 and Raphaèle Seror37, 1Rheumatology department, Kremlin Bicêtre hospital, APHP, Paris, France, 2Inserm DR Paris 5, Paris, France, 3Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, 4Hôpital Cochin, Paris, France, 5APHP, Le Kremlin Bicêtre, France, 6Rheumatology Department, Cochin Hospital, APHP, Paris, France, 7APHP, Paris, France, 8CHU Tours, Tours, France, 9Bordeaux Hospital University, Bordeaux, France, 10CHU Lyon, Lyon, France, 11department of Internal Medecine, CHU de Tours, Tours, France, 12CHU Rouen, Rouen, France, 13CHU Nice, Nice, France, 14Hopital Saint Antoine, Paris, France, 15CHU Poitiers, Poitiers, France, 16Université de Bordeaux, Bordeaux, France, 17Université de Lille, Lille, France, 18Hôpitaux privés de Metz, Metz, France, 19CHU Brest, Brest, France, 20CHU Reims, Reims, France, 21Saint Joseph Hospital, Marseille, France, 22CHU Mondor, Creteil, France, 23CH La Réunion, CH la Réunion, France, 24CH Cabestany, Cabestany, France, 25CH Saint Joseph Saint Luc, Lyon, France, 26CHU Grenoble, CHU Grenoble, France, 27CH St Denis Reunion, Saint Denis Reunion, France, 28University Hospital, Clermont-Ferrand, France, 29CHU Caen, Caen, France, 30APHM, Marseille, France, 31CHU Rennes, Rennes, France, 32CHU Saint Etienne, Saint Etienne, France, 33Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 34Jean Verfier, Bobigny, France, 35Port Royal, Paris, France, 36Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 37University Hospital Paris-Saclay, Le Kremlin Bicêtre, France

    Background/Purpose: In the context of primary Sjögren's syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes…
  • Abstract Number: 2016 • ACR Convergence 2022

    Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Andriko Palmowski1, Sabrina Mai Nielsen2, Zhivana Boyadzhieva3, Abelina Schneider3, Anne Pankow3, Linda Hartman4, Jose Pereira da Silva5, John Kirwan6, Siegfried Wassenberg7, Christian Dejaco8, Robin Christensen9, Maarten Boers10 and Frank Buttgereit11, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, 5University of Coimbra, Rheumatology, Columbia, Portugal, 6University of Bristol, Bristol, United Kingdom, 7Rheumazentrum Ratingen, Ratingen, Germany, 8Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 9Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 10Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 11Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
  • Abstract Number: 2017 • ACR Convergence 2022

    Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome

    Juliette Rocca1, Maxime Beydon2, Veronique Le Guern3, Eric Hachulla4, Jean Jacques Dubost5, sandrine jousse joulin6, Valerie Devauchelle7, Jacques-Eric Gottenberg8, Olivier Vittecoq9, Christian Lavigne10, Jean Schmidt11, Christian Marcelli12, Claire Larroche13, Xavier Mariette14, Raphaèle Seror15 and Gaetane Nocturne16, 1APHP, Paris, France, 2Université Paris Cité, Paris, France, 3Hôpital Cochin, Paris, France, 4University of Lille, LILLE, France, 5University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, 6Roche, Brest, France, 7Université de Bretagne Occidentale, Brest, France, 8University of Strasbourg, Strasbourg, France, 9CHU de Rouen, ROUEN, France, 10CHU Angers, Angers, France, 11CHU Amiens, Amiens, France, 12CHU Caen, Caen, France, 13APHP, Bobigny, France, 14Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 15University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, 16APHP, Le Kremlin Bicêtre, France

    Background/Purpose: Primary Sjögren Syndrome (pSS) patients present an increased risk of Non-Hodgkin lymphoma (NHL). There is no consensus on the therapeutic management of low-grade NHL.…
  • Abstract Number: 2008 • ACR Convergence 2022

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs

    Alan Kivitz1, Liangwei Wang2, Ilias Alevizos2, Michele Gunsior2, Judith Falloon2 and Gabor Illei3, 1Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 2Horizon Therapeutics, Gaithersburg, MD, 3Horizon Therapeutics, Rockville, MD

    Background/Purpose: Dazodalibep (DAZ), a non-antibody biologic antagonist of CD40L, led to higher/durable response rates vs. placebo (PBO) in a double-blind, Phase 1b trial of patients…
  • Abstract Number: 1999 • ACR Convergence 2022

    Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)

    Vibeke Strand1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1Stanford University School of Medicine, Stanford, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA

    Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
  • Abstract Number: 1980 • ACR Convergence 2022

    Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage

    Céleste van der Togt1, David Ten Cate1, Janette Rahamat-Langendoen2, Bart van den Bemt3, Nathan den Broeder4 and Alfons den Broeder4, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, 3Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, 4Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
  • Abstract Number: 1907 • ACR Convergence 2022

    Strength Training Associates with Less Knee Osteoarthritis: Data from the Osteoarthritis Initiative

    Grace Lo1, Michael Richard2, Timothy McAlindon3, Andrea Kriska4, Bonny Rockette-Wagner4, Charles Eaton5, Marc Hochberg6, Rebecca Jackson7, Kent Kwoh8, Michael Nevitt9 and Jeffrey Driban10, 1Baylor College of Medicine, Houston, TX, 2Tufts Medical Center, Boston, MA, 3Tufts Medical Center, Arlington, MA, 4University of Pittsburgh, Pittsburgh, PA, 5Brown University, Pawtucket, RI, 6University of Maryland School of Medicine, Baltimore, MD, 7The Ohio State University, Columbus, OH, 8University of Arizona, Tucson, AZ, 9University of California San Francisco, Orinda, CA, 10Tufts Medical Center, Westborough, MA

    Background/Purpose: Engagement in strength training has become increasingly popular and is an activity that can involve weight-bearing, heavy lifting, and frequent knee bending; and thus…
  • Abstract Number: 2027 • ACR Convergence 2022

    Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome

    Uzma Nakshbandi1, Martha S. van Ginkel1, Silvia Liefers2, Hendrika Bootsma2, Fred Spijkervet2, Arjan Vissink1, Bert van der Vegt1 and Frans Kroese2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
  • Abstract Number: 2028 • ACR Convergence 2022

    The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome

    Martha S. van Ginkel1, Andor WJM Glaudemans1, Bert van der Vegt1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
  • Abstract Number: 1911 • ACR Convergence 2022

    Baseline Bone Curvature a Biomarker for the Prediction of Knee Osteoarthritis Cartilage Volume Loss at One-Year. Use of Machine Learning

    Johanne Martel-Pelletier1, Hossein Bonakdari1, Jean-Pierre Pelletier1 and François Abram2, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montréal, QC, Canada, 2ArthroLab Inc., Montréal, QC, Canada

    Background/Purpose: The hallmark of osteoarthritis is the loss of cartilage. At present, we cannot discriminate, early during the osteoarthritis process, patients for whom cartilage will…
  • Abstract Number: 1890 • ACR Convergence 2022

    The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Patients with Knee Osteoarthritis: a Non-inferiority, Randomized, Controlled, Double-blind, Multicenter Study

    Sumapa Chaiamnuay1, Komchan Utamawatin2, Ong-art Phruetthiphat2 and Rit Apinyankul3, 1Phramongkutklao hospital, Nonthaburi, Thailand, 2Phramongkutklao Hospital, Bangkok, Thailand, 3Konkaen University Hospital, Konkaen, Thailand

    Background/Purpose: Intra-articular (IA) corticosteroid injection is recommended in refractory knee osteoarthritis patients. However, 40-mg of triamcinolone IA every 3 months for 2 years reduces cartilage…
  • Abstract Number: 1902 • ACR Convergence 2022

    Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials

    Yusuf Yazici1, Christopher Swearingen2, Heli Ghandehari3, ismail simsek4, Sarah Kennedy5, Jeyanesh Tambiah6 and Timothy McAlindon7, 1New York University School of Medicine, La Jolla, CA, 2Samumed LLC, San Diego, CA, 3Biosplice Therapeutics, Inc., San Diego, CA, 4Alpine Immunesciences, San Diego, CA, 5Biosplice Therapeutics, Inc, San Diego, CA, 6Biosplice Ther Inc., San Diego, CA, 7Tufts Medical Center, Arlington, MA

    Background/Purpose: Osteoarthritis (OA) is a leading cause of disability globally, and its disease burden is expected to increase as risk factors such as aging and…
  • Abstract Number: 1392 • ACR Convergence 2022

    Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic

    Maria Mirza1, Kaiyang Song1, Madiha Ashraf2, Anushka Soni3, John Jackman3 and Raashid Luqmani1, 1Oxford University Hospital, Oxford, United Kingdom, 2Oxford Universtiy Hospital, Oxford, United Kingdom, 3Oxford University Hospital, Oxford, England, United Kingdom

    Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported…
  • « Previous Page
  • 1
  • …
  • 446
  • 447
  • 448
  • 449
  • 450
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology